Page last updated: 2024-12-07

diprotin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
Cereusgenus[no description available]CactaceaeThe cactus plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. Cacti are succulent perennial plants well adapted to dry regions.[MeSH]

Cross-References

ID SourceID
PubMed CID94701
CHEMBL ID214381
CHEBI ID93213
SCHEMBL ID6404766
MeSH IDM0122931

Synonyms (38)

Synonym
IPI ,
90614-48-5
BRD-K69032158-001-02-2
diprotin a ,
BCBCMAP01_000164
l-isoleucine, n-(1-l-isoleucyl-l-prolyl)-
ile-pro-ile
n-(1-l-isoleucyl-l-prolyl)-l-isoleucine
isoleucyl-prolyl-isoleucine
SMP1_000085
BSPBIO_003515
KBIO3_003020
SPECTRUM3_001838
SPBIO_001439
SPECTRUM2_001480
NCGC00178015-01
(2s,3s)-2-((s)-1-((2s,3s)-2-amino-3-methylpentanoyl)pyrrolidine-5-carboxamido)-3-methylpentanoic acid
bdbm50229666
CHEMBL214381 ,
l-isoleucyl-l-prolyl-l-isoleucine
isoleucylprolylisoleucine
CCG-38872
SCHEMBL6404766
JNTMAZFVYNDPLB-PEDHHIEDSA-N
mfcd00038707
AKOS030210980
diprotin a (h-l-ile-l-pro-l-ile-oh)
CHEBI:93213
CS-0034521
HY-111174
n-[hydroxy(1-isoleucylpyrrolidin-2-yl)methylidene]isoleucine
DTXSID80920277
dipeptidyl peptidase iv inhibitor
diprotin a (ile-pro-ile)
(2s,3s)-2-[[[(2s)-1-[(2s,3s)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid
Q27164930
(2s,3s)-2-((s)-1-((2s,3s)-2-amino-3-methylpentanoyl)pyrrolidine-2-carboxamido)-3-methylpentanoic acid
MS-25221

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The following study addressed the hypothesis that neuropeptide Y bioavailability is blunted in female rats under baseline conditions."( Neuropeptide Y bioavailability is suppressed in the hindlimb of female Sprague-Dawley rats.
Jackson, DN; Milne, KJ; Noble, EG; Shoemaker, JK, 2005
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Because AMD3100 is known to mobilize bone marrow derived stem cells (BMCs) in high concentrations, the optimal dosage (1."( Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis.
Assmann, G; Brunner, S; Fischer, R; Franz, WM; Gröbner, M; Hacker, M; Huber, B; Krieg, L; Mueller-Hoecker, J; Rischpler, C; Theiss, HD; Vallaster, M; Vanchev, Y; Wollenweber, T; Zaruba, MM, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
peptideAmide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dipeptidyl peptidase 4Sus scrofa (pig)IC50 (µMol)14.40000.43001.14002.5000AID313844
Dipeptidyl peptidase 4Homo sapiens (human)IC50 (µMol)3.60500.00010.444410.0000AID1395903; AID581755
Dipeptidyl peptidase 4Homo sapiens (human)Ki2.20000.00000.34142.2000AID1096868; AID1096869
Tripeptidyl-peptidase 2Rattus norvegicus (Norway rat)Ki1.00000.00700.50351.0000AID214629
Dipeptidyl peptidase 8Homo sapiens (human)Ki39.00000.00150.46241.3420AID581756
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (23)

Processvia Protein(s)Taxonomy
behavioral fear responseDipeptidyl peptidase 4Homo sapiens (human)
response to hypoxiaDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 4Homo sapiens (human)
cell adhesionDipeptidyl peptidase 4Homo sapiens (human)
positive regulation of cell population proliferationDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of extracellular matrix disassemblyDipeptidyl peptidase 4Homo sapiens (human)
peptide hormone processingDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellDipeptidyl peptidase 4Homo sapiens (human)
T cell costimulationDipeptidyl peptidase 4Homo sapiens (human)
regulation of cell-cell adhesion mediated by integrinDipeptidyl peptidase 4Homo sapiens (human)
locomotory exploration behaviorDipeptidyl peptidase 4Homo sapiens (human)
psychomotor behaviorDipeptidyl peptidase 4Homo sapiens (human)
T cell activationDipeptidyl peptidase 4Homo sapiens (human)
endothelial cell migrationDipeptidyl peptidase 4Homo sapiens (human)
symbiont entry into host cellDipeptidyl peptidase 4Homo sapiens (human)
receptor-mediated virion attachment to host cellDipeptidyl peptidase 4Homo sapiens (human)
negative chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
membrane fusionDipeptidyl peptidase 4Homo sapiens (human)
negative regulation of neutrophil chemotaxisDipeptidyl peptidase 4Homo sapiens (human)
glucagon processingDipeptidyl peptidase 4Homo sapiens (human)
proteolysisDipeptidyl peptidase 8Homo sapiens (human)
apoptotic processDipeptidyl peptidase 8Homo sapiens (human)
immune responseDipeptidyl peptidase 8Homo sapiens (human)
negative regulation of programmed cell deathDipeptidyl peptidase 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
virus receptor activityDipeptidyl peptidase 4Homo sapiens (human)
protease bindingDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
serine-type endopeptidase activityDipeptidyl peptidase 4Homo sapiens (human)
signaling receptor bindingDipeptidyl peptidase 4Homo sapiens (human)
protein bindingDipeptidyl peptidase 4Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 4Homo sapiens (human)
identical protein bindingDipeptidyl peptidase 4Homo sapiens (human)
protein homodimerization activityDipeptidyl peptidase 4Homo sapiens (human)
chemorepellent activityDipeptidyl peptidase 4Homo sapiens (human)
aminopeptidase activityDipeptidyl peptidase 8Homo sapiens (human)
protein bindingDipeptidyl peptidase 8Homo sapiens (human)
serine-type peptidase activityDipeptidyl peptidase 8Homo sapiens (human)
dipeptidyl-peptidase activityDipeptidyl peptidase 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
extracellular regionDipeptidyl peptidase 4Homo sapiens (human)
lysosomal membraneDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
focal adhesionDipeptidyl peptidase 4Homo sapiens (human)
cell surfaceDipeptidyl peptidase 4Homo sapiens (human)
membraneDipeptidyl peptidase 4Homo sapiens (human)
apical plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
lamellipodiumDipeptidyl peptidase 4Homo sapiens (human)
endocytic vesicleDipeptidyl peptidase 4Homo sapiens (human)
lamellipodium membraneDipeptidyl peptidase 4Homo sapiens (human)
membrane raftDipeptidyl peptidase 4Homo sapiens (human)
intercellular canaliculusDipeptidyl peptidase 4Homo sapiens (human)
extracellular exosomeDipeptidyl peptidase 4Homo sapiens (human)
plasma membraneDipeptidyl peptidase 4Homo sapiens (human)
cytoplasmDipeptidyl peptidase 8Homo sapiens (human)
cytoplasmDipeptidyl peptidase 8Homo sapiens (human)
cytosolDipeptidyl peptidase 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1395903Inhibition of DPP4 (unknown origin) using Gly-Pro-AMC as substrate preincubated for 4 secs followed by substrate addition and measured after 30 mins by luminescence assay2018European journal of medicinal chemistry, May-10, Volume: 151Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
AID1096868Inhibition of DPP-4 (unknown origin) assessed as inhibition of endomorphin-1 degradation after 30 min2012Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, Jul, Volume: 21, Issue:7
Kinetic studies of novel inhibitors of endomorphin degrading enzymes.
AID1096869Inhibition of DPP-4 (unknown origin) assessed as inhibition of endomorphin-2 degradation after 30 min2012Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, Jul, Volume: 21, Issue:7
Kinetic studies of novel inhibitors of endomorphin degrading enzymes.
AID1096871Inhibition of DPP-4 (unknown origin) assessed as half-life of endomorphin-2 after 30 min by RP-HPLC analysis (Rvb = 10.9 +/- 0.64 min)2012Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, Jul, Volume: 21, Issue:7
Kinetic studies of novel inhibitors of endomorphin degrading enzymes.
AID269618Inhibition of bovine serum-catalyzed prodrug Val-Pro-NAP-TSAO-T conversion to parent drug NAP-TSAO-T2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach.
AID581755Inhibition of human recombinant DPP4 assessed as Gly-Pro-pNA chromogenic substrate cleavage for 16 mins preincubated with compound for 10 mins before addition of chromogenic substrate2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID269617Inhibition of human serum-catalyzed prodrug Val-Pro-NAP-TSAO-T conversion to parent drug NAP-TSAO-T2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach.
AID594488Inhibition of DPP4 at 10 uM assessed as p-nitrophenol release after 1 hr relative to control2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1096870Inhibition of DPP-4 (unknown origin) assessed as half-life of endomorphin-1 after 30 min by RP-HPLC analysis (Rvb = 16.7 +/- 0.52 min)2012Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, Jul, Volume: 21, Issue:7
Kinetic studies of novel inhibitors of endomorphin degrading enzymes.
AID1172857Inhibition of DPP4 in human plasma using Gly-Pro-AMC substrate incubated for 20 mins by fluorometry2014Bioorganic & medicinal chemistry, Nov-15, Volume: 22, Issue:22
Thiophenes, polyacetylenes and terpenes from the aerial parts of Eclipata prostrate.
AID581756Inhibition of human recombinant DPP8 assessed as Gly-Pro-pNA chromogenic substrate cleavage for 16 mins preincubated with compound for 10 mins before addition of chromogenic substrate2010ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9
Design, Synthesis, and in Vitro Evaluation of Novel Aminomethyl-pyridines as DPP-4 Inhibitors.
AID594491Inhibition of DPP8 at 10 uM assessed as p-nitrophenol release after 1 hr relative to control2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists.
AID269616Inhibition of CD26-catalyzed prodrug Val-Pro-NAP-TSAO-T conversion to parent drug NAP-TSAO-T2006Journal of medicinal chemistry, Aug-24, Volume: 49, Issue:17
Design and discovery of a novel dipeptidyl-peptidase IV (CD26)-based prodrug approach.
AID313844Inhibition of pig DPP42008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
AID214629Inhibition potency against Cholecystokinin-8-Inactivating Peptidase (Serine Peptidase).2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
Inhibitors of tripeptidyl peptidase II. 2. Generation of the first novel lead inhibitor of cholecystokinin-8-inactivating peptidase: a strategy for the design of peptidase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (75)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (2.67)18.7374
1990's7 (9.33)18.2507
2000's36 (48.00)29.6817
2010's29 (38.67)24.3611
2020's1 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.53 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other77 (97.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]